KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (OTC BB: GCAN) a developer of immunotherapies for the treatment cancer and other diseases, today announced that Patrick Schnegelsberg, Chief Executive Officer, is scheduled to present GammaCan’s second generation product under development for the treatment of melanoma – VitiGam, to the investor community at the Sachs Associates’ Biotech Investor Forum in Europe.
